A clinical trial involving individuals genetically predisposed to develop early-onset Alzheimer’s disease suggests that ...

For individuals with dominantly inherited Alzheimer disease, long-term treatment with gantenerumab may delay clinical decline ...

For some people with a high risk of Alzheimer's who received a drug called gantenerumab for eight years, their risk of ...

A new study conducted by researchers from the Washington University School of Medicine identified an experimental drug that ...

The study evaluated Roche’s gantenerumab in 73 participants aged between 30 to 50 with rare, inherited genetic mutations that ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

Washington University School of Medicine led a study evaluating long-term gantenerumab treatment in individuals with ...

An early Alzheimer's treatment that removes amyloid plaques from the brain many years before symptoms arise may help delay ...

Long-term removal of amyloid beta in people genetically destined to develop Alzheimer's disease may have delayed symptoms and ...

A study of Roche's anti-amyloid drug gantenerumab has suggested that early treatment to remove amyloid plaques from the brain ...

But new data from a recent clinical trial suggests that a previously discontinued experimental drug, called gantenerumab, ...

"I am highly optimistic now, as this could be the first clinical evidence of what will become preventions for people at risk for Alzheimer's disease." HealthDay News — For individuals with ...